The Cystic Fibrosis Foundation along with directors of Colorado's Cystic Fibrosis care centers sent a letter to the state's Prescription Drug Affordability Board commenting on the list of prioritized drugs eligible for an affordability review.
The Cystic Fibrosis Foundation, European Cystic Fibrosis Society, and Cystic Fibrosis Europe provided comments to the European Medicines Agency on draft guidance on establishing efficacy of a new treatment based on single-arm trials.
The Foundation sends a letter to leaders of the House Energy & Commerce Committee urging passage of H.R. 3008, 3793 and 3810 which would help mitigate drug shortages and ensure patients will have access to all necessary medications.
In a letter sent to Colorado’s Prescription Drug Affordable Board, the Cystic Fibrosis Foundation provides feedback on the board’s review of Trikafta®, including concerns around the board’s proposed methodology, and provides a compilation of published data on Trikafta’s effects on clinical outcomes and other health care utilization.
Ad hoc patient coalition provides comments to the Centers for Medicare and Medicaid Services on draft guidance related to the Medicare Prescription Payment Plan, arguing the importance of the plan in ultimately lowing the cost of prescription drugs for enrollees.
CF Foundation provides comments to the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services responding to the 2024 Medicare Physician Fee Schedule, focusing on improving access to care through telehealth.
Partnership to Protect Coverage provides comments to the U.S. Department of Health and Human Services, the Treasury Department, and the Department of Labor on a proposed rule concerning short-term, limited-duration insurance plans.